



Evidentia Publishing

Evidence in Medicine

RenalMed Transplant Trial Watch: January 2014

Dear RenalMed visitor,

The Transplant Trial Watch keeps you informed about recently published Randomized Controlled Trials (RCTs) in renal transplantation.

The Centre for Evidence in Transplantation provides an Expert Review of up to 10 carefully selected new RCTs.

These RCTs are available to you in the Transplant Library database, together with all available evidence-based publications on organ transplantation. This database (officially endorsed by the Cochrane Collaboration) is a unique resource for the transplant community.

You can get access to this essential information by requesting a **free trial** and/or a **quotation** for an institutional subscription.



Kidney Transplantation

Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial.

Bansal D, Yadav AK, et al. PLoS ONE [Electronic Resource] 2013; 8(10): e75591.

The protein kinase C inhibitor sotrastaurin allows regulatory T cell function.

de Weerd A, Kho M, et al. Clinical and experimental immunology [record in progress].

Pre-emptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study.

Stoelben S, Arns W, et al. Transplant International [record in progress].

In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development.

Todeschini M, Cortinovia M, et al. Journal of Immunology 2013; 191(5): 2818-2828.


Various Organs

Oral and intravenous thyroxine (T4) achieve comparable serum levels for hormonal resuscitation protocol in organ donors: a randomized double-blinded study.

Sharpe MD, van Rassel B, et al. Canadian Journal of Anaesthesia 2013; 60(10): 998-1002.

Other

Randomized, double-blind, placebo-controlled, dose-escalating phase I, healthy subjects study of intravenous OPN-305, a humanized anti-TLR2 antibody.



Other News

- The **Cochrane Collaboration** has endorsed the Transplant Library recognizing it as a unique, evidence-based resource for the transplant community.
- Most Viewed Article in Dec 2013: "A randomized, crossover pharmacokinetic study comparing generic tacrolimus vs. the reference formulation in subpopulations of kidney transplant patients" (<http://bit.ly/1lwnQOH>). Congratulations **Prof. RD Bloom from the Perelman School of Medicine**, Univ of Pennsylvania.
- Interested in improving your skills in **evidence-based decision making**? [Sign up](#) to ESOT's Evidence in Transplantation (EVIT) course, held March 21-22, 2014 in London.

You are receiving this mail because you opted for a monthly Transplant Trial Watch. You can unsubscribe at any time.

[Edit your subscription](#) | [Unsubscribe](#)

